References
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
- National Cancer Information Center. National statistics of cancer registration 2012 [Internet]. Goyang: National Cancer Infermation Center. Available from: http://www.cancer.go.kr/ebook/104/PC/104.html.
- Park SR, Kang YK. Perioperative treatments for resectable gastric cancer. J Korean Med Assoc 2015;58:201-218.
- Kim TY, Oh DY, Bang YJ. Treatment for unresectable gastric cancer. J Korean Med Assoc 2015;58:209-215.
- Ahn JS, Ryu SW, Kim IH, Sohn SS. Clinicopathological Analysis of Recurrent Gastric Cancer after Curative Resection. J Korean Surg Soc 2003;65:210-216.
- Iwanaga T, Koyama H, Furukawa H, Taniguch H, Wada A, Tatelshi R. Mechanisms of late recurrence after radical surgery for gastric carcinoma. Am J Surg 1978;135:637-640.
- Koga S, Takebayashi M, Kaibara N, et al. Pathological characteristics of gastric cancer that develop hematogenous recurrence, with special reference to the site of recurrence. J Surg Oncol 1987;36:239-242.
- Papachristou DN, Fortner JG. Local recurrence of gastric adenocarcinomas after gastrectomy. J Surg Oncol 1981;18:47-53.
- Lee HJ, Cho SJ, Yang HK, Lee KU, Choe KJ, Kim JP. Retrospective analysis of treatment results of recurrent gastric cancer. J Korean Cancer Assoc 2000;32:506-515.
- Bamias A, Pavlidis N. Systemic Chemotherapy in Gastric Cancer: Where Do We Stand Today? Oncologist 1998;3:171-177.
- Kang YK, Kang WK, Shin DB et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20:666-673.
- Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008;9:215-221.
- Cunningham D, Okines AF, Ashley S. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2010;362:858-859.
- Park JM, Kim YH. Current approaches to gastric cancer in Korea. Gastrointestinal cancer research: GCR. 2008;2:137.
- Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-697.
- Kang JH, Lee SI, Lim DH, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 2012;30:1513-1518.
- Thuss-Patience PC, Kretzschmar A, Bichev D, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 2011;47:2306-2314.
- Lee JH, Kim JG, Jung HK, et al. [Synopsis on clinical practice guideline of gastric cancer in Korea: an evidence-based approach]. Korean J Gastroenterol 2014;63:66-81.
- Kim BH, Eom KY, Kim JS, Kim HH, Park DJ. Role of salvage radiotherapy for regional lymph node recurrence after radical surgery in advanced gastric cancer. Radiat Oncol J 2013;31:147-154.